IP Library Granted Patent US 7,271,165
Granted Patent B2
US 7,271,165 · App. 11/020,870 · Granted Sep 18, 2007

Rifamycin analogs and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,271,165
App. No.
11/020,870
Granted
Sep 18, 2007
Kind
B2
Abstract

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′- and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.

Claims (14)

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof; wherein

A is H, OH, or O—(C 1-6 alkyl);

W is O, S, or NR 1 , wherein R 1 is H, or C 1-6 alkyl;

X is H or COR 2 , wherein R 2 is C 1-6 alkyl or O—(C 3-7 alkyl);

Y is H, Hal, or OR Y3 , wherein R Y3 is H or C 1-6 alkyl;

Z is H, Hal, or OR Z3 , wherein R Z3 is H or C 1-6 alkyl; and

R 4 is

 wherein R 22 is H, C 1-6 alkyl, C 6-12 aryl, COR 24 , CO 2 R 24 , CONHR 24 , CSR 24 , COSR 24 , CSOR 24 , CSNHR 24 , SO 2 R 24 , or SO 2 NHR 24 , wherein R 24 is C 1-6 alkyl or C 6-12 aryl, and r is 1 or 2.

2. The compound of claim 1 , wherein A is H or OH; and X is H or COCH 3 .

3. The compound of claim 1 , wherein R 4 is

4. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

5. 3′-hydroxy-5′-(3,8-diazabicyclo[3.2.1]octan-3-yl)benzoxazinorifamycin or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising 3′-hydroxy-5′-(3,8-diazabicyclo[3.2.1]octan-3-yl)benzoxazinorifamycin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2008
From: FINN JR.,JOSEPH F., AS ASSIGNEE FOR THE BENEFIT OF CREDITORS OF ACTIVBIOTICS, INC.
To: ACTIVBIOTICS PHARMA LLC
Reel/Frame 020866/0584 →
RELEASE OF SECURITY INTEREST Recorded Apr 18, 2008
From: HORIZON TECHNOLOGY FUNDING COMPANY LLC
To: ACTIVBIOTICS, INC.
Reel/Frame 020835/0427 →
SECURITY AGREEMENT Recorded Jan 7, 2008
From: ACTIVBIOTICS, INC.
To: HORIZON TECHNOLOGY FUNDING COMPANY, LLC
Reel/Frame 020325/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2005
From: VAN DUZER, JOHN H.; MICHAELIS, ARTHUR F.; SIEDLECKI, JAMES M.
To: ACTIVBIOTICS, INC.
Reel/Frame 016252/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2005
From: GEISS, WILLIAM B.; STAFFORD, DOUGLAS G.; RAKER, JOSEPH; YU, XIANG Y.; YANG, YINGFEI
To: ACTIVBIOTICS, INC.
Reel/Frame 016189/0351 →